Baxter meets primary efficacy endpoint in phase 3 trial of BAX 111
Baxter announced topline results from a Phase 3 clinical trial evaluating safety, efficacy and pharmacokinetics of BAX 111. BAX 111 is a recombinant von Willebrand factor under investigation for the treatment of bleeding episodes in patients with von Willebrand disease. April 16, 2014